Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1995 1
1997 2
1998 2
1999 2
2000 2
2001 4
2002 3
2003 3
2004 7
2005 2
2006 3
2007 19
2008 37
2009 39
2010 42
2011 67
2012 52
2013 38
2014 39
2015 30
2016 27
2017 28
2018 34
2019 22
2020 22
2021 21
2022 5
Text availability
Article attribute
Article type
Publication date

Search Results

473 results
Results by year
Filters applied: . Clear all
Page 1
Genomic and phenotypic heterogeneity in prostate cancer.
Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI, De Marzo AM, Nelson PS, Yegnasubramanian S. Haffner MC, et al. Nat Rev Urol. 2021 Feb;18(2):79-92. doi: 10.1038/s41585-020-00400-w. Epub 2020 Dec 16. Nat Rev Urol. 2021. PMID: 33328650 Free PMC article. Review.
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. Antonarakis ES, et al. N Engl J Med. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3. N Engl J Med. 2014. PMID: 25184630 Free PMC article.
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL. Brahmer JR, et al. J Clin Oncol. 2010 Jul 1;28(19):3167-75. doi: 10.1200/JCO.2009.26.7609. Epub 2010 Jun 1. J Clin Oncol. 2010. PMID: 20516446 Free PMC article. Clinical Trial.
Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses.
Aggen DH, Ager CR, Obradovic AZ, Chowdhury N, Ghasemzadeh A, Mao W, Chaimowitz MG, Lopez-Bujanda ZA, Spina CS, Hawley JE, Dallos MC, Zhang C, Wang V, Li H, Guo XV, Drake CG. Aggen DH, et al. Clin Cancer Res. 2021 Jan 15;27(2):608-621. doi: 10.1158/1078-0432.CCR-20-1610. Epub 2020 Nov 4. Clin Cancer Res. 2021. PMID: 33148676 Free PMC article.
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, Tangsombatvisit S, Grosso JF, Netto G, Smeltzer MP, Chaux A, Utz PJ, Workman CJ, Pardoll DM, Korman AJ, Drake CG, Vignali DA. Woo SR, et al. Cancer Res. 2012 Feb 15;72(4):917-27. doi: 10.1158/0008-5472.CAN-11-1620. Epub 2011 Dec 20. Cancer Res. 2012. PMID: 22186141 Free PMC article.
NKX3.1 as a marker of prostatic origin in metastatic tumors.
Gurel B, Ali TZ, Montgomery EA, Begum S, Hicks J, Goggins M, Eberhart CG, Clark DP, Bieberich CJ, Epstein JI, De Marzo AM. Gurel B, et al. Am J Surg Pathol. 2010 Aug;34(8):1097-105. doi: 10.1097/PAS.0b013e3181e6cbf3. Am J Surg Pathol. 2010. PMID: 20588175 Free PMC article.
473 results